Promega builds plant to produce regulated products

Published: 29-Aug-2011
Manufacturing Analysis

Including sample preparation systems and reagents

Promega Corporation, based in Madison, Wisconsin, US, has held a ground-breaking ceremony for a new cGMP facility to support business growth and customers who need FDA-regulated molecular biology products. These include sample preparation systems and reagents, which are part of diagnostic and medical tests sold by human diagnostic test providers.

The 260,000ft2 (24,150m2) facility will require an additional 100 people in the next five years. Most of the building will be dedicated to fixed and flexible manufacturing areas. It will also house a customer experience centre for training, laboratory demonstrations and conferences.

‘This building is our next step in expanding our product supply capabilities worldwide,’ said ceo Bill Linton.

Plans include a number of sustainable practices, including geothermal heating and cooling, dark sky compliant lighting, prairie restoration, bio-retention ponds for storm water run off among other sustainable features and construction practices.

Promega Corporation provides solutions and technical support to the life sciences industry. Its 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification.

See more

You may also like

Ingredients

Promega unveils cellular target engagement technology

Read more
TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery

Trending Articles

  1. Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
  2. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Accelerating the development of bispecific antibodies Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market
  4. Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
  5. UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline

Upcoming event

Making Pharmaceuticals

21–22 April 2026 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Promega unveils cellular target engagement technology

TarSeer BRETSA platform enables early-stage studies for difficult proteins in drug discovery
Manufacturing

Promega opens new Shanghai facility

Provides additional r&d and cGMP manufacturing capabilities
Manufacturing

Biopharma firms favour European contract manufacturing over US sites despite tariff pressure

US contract manufacturing deals for FDA-approved drugs hit a five-year low in 2025, as biopharma companies (including major US-headquartered firms) increasingly direct outsourced production to European facilities, new GlobalData analysis reveals
Manufacturing

Touchlight partners with SVF Vaccines to advance dual hepatitis B/D vaccine into clinical development

The pair will progress an innovative dual-targeting hepatitis B and D vaccine into clinical trials, leveraging Touchlight's enzymatic doggybone DNA platform, which has demonstrated significant dose-sparing potential compared to traditional plasmid DNA
Manufacturing

An integrated path: how CDMOs are reshaping complex drug development

The pharmaceutical CDMO sector is rapidly evolving toward integrated, end-to-end partnerships that align development, manufacturing, packaging and supply to meet the growing complexity, cost pressures and scalability demands of advanced biologics and precision therapies
Manufacturing

Pharmaceutical labelling in focus at Interpack 2026

Well prepared for new requirements. The upcoming reform of EU pharmaceutical legislation is expected to bring stricter requirements for traceability and labelling. The new 152E HC wrap-around labelling machine, developed specifically for contract packers, covers a wide product range with minimal change parts. Also on display: specialised labelling machines for automated product handling of small batches and high-speed labelling applications.
Manufacturing

Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system

Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
Subscribe now